Topline data were announced from a phase 3 trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.
The trial of the once-daily drug—which mimics a gut hormone known as GLP-1 to control blood sugar and suppress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback